Jubilant Radiopharma, a business division of Jubilant Pharma Ltd., is an industry-leading radiopharmaceutical business focused on developing, manufacturing, commercializing and distributing high quality and sustainable diagnostic and therapeutic agents for the sole purpose of “Improving Lives Through Nuclear Medicine” on a global scale. It is well recognized as a ‘Partner of Choice’ by leading pharmaceutical companies globally. The Company has a team of more than 5,000 multicultural people worldwide and is committed to delivering value to its customers spread across over 75 countries. Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and a wholly-owned subsidiary of Jubilant Pharmova Limited, is an integrated global Pharmaceutical company engaged in manufacturing and supply of Radiopharmaceuticals, with a network of 48 radiopharmacies in the US, Allergy Therapy Products, Contract Manufacturing of Sterile Injectables and Non-sterile products, APIs and Solid Dosage Formulations through six manufacturing facilities that produce for regulated markets including USA, Canada, Europe and other geographies.
Ga 68 netspot generator#
With the GalliaPharm ® Ge-68/Ga-68 generator and Yttriga, sterile Yttrium-90 chloride solution, Radiopharma GmbH provides two core pharmaceutical products for diagnosis and therapy.
The company is specialized in the field of nuclear medicine and molecular imaging, providing radiopharmaceuticals and radiochemicals for diagnosis, treatment and research purposes. Eckert & Ziegler Radiopharma GmbH is also a holder of a Type II Drug Master File (#28741) in the USA.Īccording to CNETS, with approximately 12,000 – 15,000 1 Canadians living with NETs, this form of cancer has gone from being once rare to one of the fastest-growing classes of cancer worldwide.”ġ CNETS – Canadian Neuroendocrine Tumor SocietyĮckert & Ziegler Radiopharma GmbH is a wholly owned subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG and part of Eckert & Ziegler’s Medical business segment. It is registered as a medicinal product in 17 European countries and Canada. GalliaPharm ® is available with the following activities: 740 MBq, 1110 MBq, 1480 MBq and 1850 MBq (20 mCi, 30 mCi, 40 mCi, 50 mCi). “As the exclusive distribution partner of the GalliaPharm ® generator in Canada, we are very pleased to provide state-of-the-art diagnostic services to more Canadian patients suffering from cancer, while also helping healthcare professionals realize the value of new and novel nuclear medicine products”, stated Sergio Calvo, President of Jubilant’s Radiopharmaceuticals Division.
“Therefore, after the successful approval of GalliaPharm ® by Health Canada in 2020, this marks another important milestone for making such diagnostics broadly available to nuclear medicine practices and clinics in Canada together with our partners from Jubilant Radiopharma™.” Harald Hasselmann, Eckert & Ziegler Executive Director and responsible for the Medical segment.
“NETSPOT ® is the only registered Ga-68 based radiopharmaceutical in Canada”, explained Dr. On JHealth Canada approved Eckert & Ziegler Radiopharma’s GalliaPharm ® Ge68/Ga-68 generator for use with Advance Accelerator Applications’ NETSpot kit used for the localization of somatostatin receptor positive neuroendocrine tumors (NET) in adult patients using Positron Emission Tomography (PET).
0 kommentar(er)
